Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Change in Accured Expenses: 2022-2024

Historic Change in Accured Expenses for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to $3.0 million.

  • Orchestra BioMed Holdings' Change in Accured Expenses rose 176.95% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 14.04%. This contributed to the annual value of $3.0 million for FY2024, which is 1947.59% up from last year.
  • Latest data reveals that Orchestra BioMed Holdings reported Change in Accured Expenses of $3.0 million as of FY2024, which was up 1,947.59% from $145,000 recorded in FY2023.
  • Orchestra BioMed Holdings' 5-year Change in Accured Expenses high stood at $3.4 million for FY2022, and its period low was $145,000 during FY2023.
  • In the last 3 years, Orchestra BioMed Holdings' Change in Accured Expenses had a median value of $3.0 million in 2024 and averaged $2.2 million.
  • Per our database at Business Quant, Orchestra BioMed Holdings' Change in Accured Expenses slumped by 95.67% in 2023 and then skyrocketed by 1,947.59% in 2024.
  • Orchestra BioMed Holdings' Change in Accured Expenses (Yearly) stood at $3.4 million in 2022, then crashed by 95.67% to $145,000 in 2023, then spiked by 1,947.59% to $3.0 million in 2024.